ArticleDigestive diseases and sciences2019
Risk Factors for the Development of Stent-Associated Cholangitis Following Endoscopic Biliary Stent Placement.
Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Biliary Stent Placement by Endoscopic Retrograde Cholangiopancreatography: Quality Indicators and Technical Applications.Gut and liver · 2026Review
- Outcomes associated with bilateral plastic versus metal stents for palliation in malignant hilar biliary obstruction: an updated meta-analysis from the United States.Clinical endoscopy · 2026Article
- Risk prediction of biliary infection after endoscopic drainage for malignant perihilar biliary obstruction: A 10-year multicenter retrospective study.World journal of gastroenterology · 2025Article
- Duration and Predictive Factors of Plastic Biliary Stent Patency: Results of a Large Prospective Database Analysis.Journal of clinical medicine · 2025Article
- Risk factors of early dysfunction after switching from plastic to metal stents in malignant extrahepatic biliary obstruction.Journal of the Chinese Medical Association : JCMA · 2025Article
- Imaging of pancreatic ductal adenocarcinoma - An update for all stages of patient management.European journal of radiology open · 2024Article
- Penetration of duodenal wall by proximal end of biliary straight plastic stent in a patient with ampullary carcinoma.DEN open · 2024Article
- Biliary co-infection by multidrug-resistantMedical mycology case reports · 2024Article
- New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures.World journal of gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTo elucidate the overall risk and risk factors for developing cholangitis following biliary stent placement by endoscopic retrograde cholangiopancreatography (ERCP) and to determine the clinical outcomes of these individuals.
methodsWe performed a retrospective review of 796 patients who had undergone 1127 ERCPs with biliary stent placement between 2007 and 2015 at a single tertiary care center. There were 91 episodes of stent-associated cholangitis (SAC) during the study period. Data obtained through the medical records included ERCP indication, patient factors (biliary anatomy, demographics, and comorbidities), stent characteristics (material, length, and design), change in serum bilirubin, stent indwelling time, rates and etiologies of bacteremia, and the mortality rate.
resultsThose with SAC were more likely to have an anatomic biliary stricture (13.1% vs. 2.3%, p < .0001), with hilar and multiple strictures having the highest risk (19.1% vs. 11.6%, p = .04). The ERCP indication of malignant biliary obstruction was associated with higher rates of SAC (15.6% vs. 3.4%, p = < .0001). Rates of SAC were higher in those who failed to normalize total bilirubin (16.9% vs. 7.8%, p = .0005), and these episodes occurred earlier compared to those who normalized total bilirubin (median 30.5 days vs. 140.5 days, p < .0001).
conclusionsPatients at increased risk of SAC include those with an anatomic stricture, malignant biliary obstruction, and those who fail to normalize total bilirubin after biliary stent placement. Future protocols should be designed to reduce the risk of cholangitis in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.